Ticker > Company >

Ajanta Pharma share price

Ajanta Pharma Ltd.

NSE: AJANTPHARM BSE: 532331 SECTOR: Pharmaceuticals & Drugs  1.19 L   533   52

2619.00
+17.75 (0.68%)
BSE: 05 Sep 04:01 PM

Price Summary

Today's High

₹ 2625.4

Today's Low

₹ 2551.5

52 Week High

₹ 3485.75

52 Week Low

₹ 2022.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

32720.64 Cr.

Enterprise Value

32670.92 Cr.

No. of Shares

12.49 Cr.

P/E

34.96

P/B

8.44

Face Value

₹ 2

Div. Yield

1.07 %

Book Value (TTM)

₹  310.16

CASH

49.72 Cr.

DEBT

0 Cr.

Promoter Holding

66.26 %

EPS (TTM)

₹  74.91

Sales Growth

8.84%

ROE

26.09 %

ROCE

33.66%

Profit Growth

13.58 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Ajanta Pharma Ltd.

Met XL Softdrops Sunstop Kamagra Melacare Cinod Feburic Forticord Zaha Ilapro

Index Presence

The company is present in 23Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year8.84%
3 Year11.23%
5 Year14.5%

Profit Growth

1 Year13.58%
3 Year8.4%
5 Year15.76%

ROE%

1 Year26.09%
3 Year22.59%
5 Year23.37%

ROCE %

1 Year33.66%
3 Year29.6%
5 Year30.57%

Debt/Equity

0

Price to Cash Flow

31.05

Interest Cover Ratio

257.5348

CFO/PAT (5 Yr. Avg.)

0.960966194081586

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 66.26 14.12
Mar 2025 66.26 12.61
Dec 2024 66.26 11.17
Sep 2024 66.26 11.17
Jun 2024 66.27 11.57
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 22.5921666666667% over the past 3 years.
  • Company has been maintaining healthy ROCE of 29.5953666666667% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 257.5348.
  • The Company has been maintaining an effective average operating margins of 27.0810390008186% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -7.41730000000001 days.
  • Company has a healthy liquidity position with current ratio of 3.6121.

 Limitations

  • The company has shown a poor profit growth of 8.39844811950492% for the Past 3 years.
  • The company has shown a poor revenue growth of 11.2302924741953% for the Past 3 years.
  • Promoter pledging has increased from 12.6113674101654% to 14.12% in 1 quarter.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 1077.27 1128.91 1101.92 1013.94 1208.56
Total Expenditure 761.44 826 765.59 764.29 879.16
Operating Profit 315.83 302.91 336.33 249.65 329.4
Other Income 28.37 40.34 33.23 17.93 40.63
Interest 0.72 0.73 2.48 0.67 0.73
Depreciation 32.92 33.32 34.93 38.76 40.31
Exceptional Items 0 0 0 0 0
Profit Before Tax 310.56 309.2 332.15 228.15 328.99
Tax 74.53 74.22 79.7 34.72 74.02
Profit After Tax 236.03 234.98 252.45 193.43 254.97
Adjusted EPS (Rs) 18.83 18.75 20.14 15.43 20.34

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 2718.59 3140.64 3411.27 3971.12 4322.04
Total Expenditure 1801.68 2249.75 2711.99 2851.69 3117.32
Operating Profit 916.91 890.89 699.28 1119.43 1204.72
Other Income 103.57 139.73 132.75 116.48 119.87
Interest 6.9 9.12 5.23 6.8 4.6
Depreciation 111.49 120.96 126.95 132.16 139.93
Exceptional Items 0 0 0 0 0
Profit Before Tax 902.09 900.54 699.85 1096.95 1180.06
Tax 226.45 180.68 141.13 289.71 263.17
Net Profit 675.64 719.86 558.72 807.24 916.89
Adjusted EPS (Rs.) 52.07 56.2 44.38 64.12 73.41

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 17.39 17.17 25.27 25.27 25.07
Total Reserves 2867.59 3152.01 3221.18 3388.3 3600.24
Borrowings 0 0 0 0 0
Other N/C liabilities 321.18 338.33 272.9 174.17 218.22
Current liabilities 706.28 469.7 907.84 629.19 710.72
Total Liabilities 3912.44 3977.21 4427.19 4217.44 4554.25
Assets
Net Block 1509.89 1483.91 1484.01 1464.89 1741.96
Capital WIP 108.19 152.86 209.47 256.45 176.27
Intangible WIP 0 0 0 0 0
Investments 17.89 42.99 42.99 37.09 43.13
Loans & Advances 230.52 226.15 134.68 12.97 13.12
Other N/C Assets 19.55 14.29 12.77 13.22 12.56
Current Assets 2026.4 2057.01 2543.27 2432.82 2567.21
Total Assets 3912.44 3977.21 4427.19 4217.44 4554.25
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 902.09 900.54 699.85 1096.95 1180.06
Adjustment 37.07 55.58 79.34 49.31 69.38
Changes in Assets & Liabilities -274.26 -220.31 82.66 -158.63 86.19
Tax Paid -197.91 -193.47 -125.56 -252.28 -281.83
Operating Cash Flow 466.99 542.34 736.29 735.35 1053.8
Investing Cash Flow -162.68 -66.04 -501.31 105.02 -349.6
Financing Cash Flow -268.9 -457.3 -105.12 -1047.7 -715.71
Net Cash Flow 35.41 19 129.86 -207.33 -11.51

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 66.27 66.26 66.26 66.26 66.26
aayush m agrawal 0.02 0.02 0.02 0.02 0.02
aayush m agrawal, trustee... 11.30 11.30 11.30 11.30 11.30
gabs investments pvt ltd 10.08 10.08 10.08 10.08 10.08
ganga exports being repre... 2.68 2.68 2.68 2.68 2.68
rajesh m agrawal, trustee... 14.48 14.47 14.47 14.47 14.47
ravi p agrawal 0.23 0.23 0.23 0.23 0.23
ravi p agrawal, trustee r... 13.01 13.00 13.00 13.00 13.00
yogesh m agrawal, trustee... 14.48 14.47 14.47 14.47 14.47
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 33.73 33.74 33.74 33.74 33.74
canara robeco mutual fund... - - - - 1.51
investor education and pr... - 0.09 - 0.09 0.09
kotak small cap fund 1.24 1.24 1.24 1.46 1.43
llp 0.03 0.03 0.02 0.02 0.02
nippon life india trustee... 3.04 2.98 2.99 2.84 2.69
tata aia life insurance c... 1.67 1.34 1.24 1.25 1.45
uti-flexi cap fund - - - 2.96 3.12
canara robeco mutual fund... - - - 1.38 -
hdfc large and mid cap fu... 1.13 1.54 1.47 1.25 -
canara robeco mutual fund... - 1.03 1.09 - -
investor education and pr... 0.09 - 0.09 - -
uti flexi cap fund 3.03 2.95 2.86 - -
aditya birla sun life tru... - 1.05 - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market
Research Report By:
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research Way2Wealth
Research ICICI Securities Limited

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY24
Concall Q3FY24
Concall Q3FY22
Concall Q2FY24
Concall Q1FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY24
Presentation Q3FY23
Presentation Q3FY21
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY21
Presentation Q1FY20
Presentation Q3FY20

Company News

Ajanta Pharma informs about analyst meet 2 Sep, 10:46 AM Ajanta Pharma informs about press release 29 Jul, 3:41 PM Ajanta Pharma - Quaterly Results 28 Jul, 2:59 PM Ajanta Pharma - Quaterly Results 28 Jul, 2:59 PM Ajanta Pharma - Quaterly Results 28 Jul, 2:59 PM Ajanta Pharma informs about outcome of AGM 18 Jul, 4:57 PM Ajanta Pharma informs about certificate 8 Jul, 9:56 AM Ajanta Pharma informs about disclosure 19 Jun, 12:49 PM Ajanta Pharma informs about disclosure 17 Jun, 1:15 PM Ajanta Pharma informs about annual secretarial compliance report 12 May, 1:06 PM Ajanta Pharma informs about written transcript of earnings call 5 May, 5:23 PM Ajanta Pharma informs about newspaper publication 2 May, 11:48 AM Ajanta Pharma - Quaterly Results 30 Apr, 3:23 PM Ajanta Pharma - Quaterly Results 30 Apr, 3:23 PM Ajanta Pharma - Quaterly Results 30 Apr, 3:23 PM Ajanta Pharma to expand manufacturing capacity 21 Mar, 2:09 PM Ajanta Pharma informs about updates 20 Mar, 5:26 PM Ajanta Pharma informs about disclosure 11 Mar, 12:01 PM Ajanta Pharma informs about disclosure 14 Feb, 11:53 AM Ajanta Pharma informs about analyst meet 7 Feb, 10:00 AM Ajanta Pharma informs about clarification on market price movement 4 Feb, 10:12 AM Ajanta Pharma - Quaterly Results 30 Jan, 3:35 PM Ajanta Pharma - Quaterly Results 30 Jan, 3:35 PM Ajanta Pharma - Quaterly Results 30 Jan, 3:35 PM Ajanta Pharma - Quaterly Results 28 Oct, 3:51 PM Ajanta Pharma - Quaterly Results 28 Oct, 3:51 PM Ajanta Pharma - Quaterly Results 28 Oct, 3:51 PM Ajanta Pharma informs about disclosure 10 Sep, 2:10 PM Ajanta Pharma informs about loss of share certificate 23 Aug, 2:13 PM Ajanta Pharma informs about disclosure 21 Aug, 5:29 PM Ajanta Pharma informs about participation in investor conference 8 Aug, 2:25 PM Ajanta Pharma reports 18% rise in Q1 consolidated net profit 30 Jul, 5:19 PM Ajanta Pharma - Quaterly Results 30 Jul, 3:01 PM Ajanta Pharma - Quaterly Results 30 Jul, 3:01 PM Ajanta Pharma - Quaterly Results 30 Jul, 3:01 PM Ajanta Pharma informs about board meeting 17 Jul, 3:14 PM Ajanta Pharma informs about compliances-certificate 11 Jul, 2:24 PM Ajanta Pharma informs about annual report and BRSR 18 Jun, 5:34 PM Ajanta Pharma informs about newspapers publication 17 Jun, 4:29 PM Ajanta Pharma informs about disclosure 4 Jun, 12:37 PM Ajanta Pharma - Quaterly Results 2 May, 4:39 PM Ajanta Pharma - Quaterly Results 2 May, 4:39 PM Ajanta Pharma - Quaterly Results 2 May, 4:39 PM Ajanta Pharma informs about compliance certificate 15 Apr, 4:53 PM Ajanta Pharma informs about disclosure 30 Mar, 3:27 PM Ajanta Pharma - Quaterly Results 31 Jan, 4:12 PM Ajanta Pharma - Quaterly Results 31 Jan, 4:12 PM Ajanta Pharma - Quaterly Results 31 Jan, 4:12 PM Ajanta Pharma submits intimation of record date 25 Jan, 12:53 PM Ajanta Pharma informs about update on board meeting 25 Jan, 10:58 AM

Ajanta Pharma Stock Price Analysis and Quick Research Report. Is Ajanta Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Ajanta Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Ajanta Pharma has a PE ratio of 34.8988719044123 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Ajanta Pharma has ROA of 20.9057% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Ajanta Pharma has a Current ratio of 3.6121.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Ajanta Pharma has a ROE of 26.093%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Ajanta Pharma has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Ajanta Pharma has reported revenue growth of 8.8368% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Ajanta Pharma for the current financial year is 27.8738743741381%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Ajanta Pharma is Rs 28 and the yield is 1.0691%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Ajanta Pharma is Rs 74.905. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Ajanta Pharma in Ticker for free. Also, one can get the intrinsic value of Ajanta Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Ajanta Pharma FAQs

Q1. What is Ajanta Pharma share price today?
Ans: The current share price of Ajanta Pharma is Rs 2614.1.

Q2. What is the market capitalisation of Ajanta Pharma?
Ans: Ajanta Pharma has a market capitalisation of Rs 32659.42146984 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Ajanta Pharma?
Ans: The PE ratio of Ajanta Pharma is 34.8988719044123 and the P/B ratio of Ajanta Pharma is 8.42820069957193, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Ajanta Pharma share?
Ans: The 52-week high share price of Ajanta Pharma is Rs 3485, and the 52-week low share price of Ajanta Pharma is Rs 2327.3.

Q5. Does Ajanta Pharma pay dividends?
Ans: Currently, Ajanta Pharma pays dividends. Dividend yield of Ajanta Pharma is around 1.0691%.

Q6. What are the face value and book value of Ajanta Pharma shares?
Ans: The face value of Ajanta Pharma shares is Rs 2, while the book value per share of Ajanta Pharma is around Rs 310.1611. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Ajanta Pharma?
Ans: Ajanta Pharma has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Ajanta Pharma?
Ans: The ROE of Ajanta Pharma is 26.093% and ROCE of Ajanta Pharma is 33.6605%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Ajanta Pharma a good buy for the long term?
Ans: The Ajanta Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Ajanta Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Ajanta Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Ajanta Pharma’s financials?
Ans: You can review Ajanta Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Ajanta Pharma

Ajanta Pharma Ltd Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Ajanta Pharma Ltd. is a pharmaceutical major that produces a diverse range of speciality and generic formulations. The company caters to healthcare needs across various therapeutic segments such as cardiovascular, dermatology, ophthalmology, pain management, and many others. As a long-term investor, knowing the ins and outs of a company is vital before investing in it. This article will provide an in-depth analysis of Ajanta Pharma Ltd.’s stocks based on several parameters.

Ajanta Pharma Ltd Share Price

Ajanta Pharma Ltd.’s share price is a key metric that is continuously monitored by traders and investors alike. The company is a part of the 'Pharmaceuticals - Indian' industry, which has seen immense growth. Fair value analysis shows that Ajanta Pharma’s stock is fairly valued in the market compared to other companies in the industry. It is important to also look at the historical performance of the company's stock price, which can be easily accessed through Ticker's pre-built screening tool.

Ajanta Pharma Ltd Balance Sheet

A company's balance sheet shows its financial health and is a key metric for investors to consider. Ajanta Pharma's financial statements reveal a healthy balance sheet with sound financial management. We offer our premium tool, DCF Analysis, which allows investors to determine the fair value of Ajanta Pharma’s stock based on the company's balance sheet.

Ajanta Pharma Ltd Annual Report

Investors can gain a deep understanding of Ajanta Pharma’s business model, financial performance, and growth prospects by studying its annual report. Ticker provides access to downloadable annual reports, which can then be studied to gain insight into the company's future plans and growth strategy.

Ajanta Pharma Ltd Dividend

Dividend payments by a company are an important source of returns for long-term investors. Ajanta Pharma has a track record of consistently paying a dividend to its shareholders. Investors can easily track the company's dividend history through Ticker's pre-built screening tool to make informed decisions.

Ajanta Pharma Ltd Quarterly Result

A company's quarterly results reflect its performance over a short period of time. Investors can use this information to note trends in the company's financial performance. Ticker provides access to Ajanta Pharma’s quarterly results as downloadable documents. Ticker premium tool, BVPS Analysis, can also be used to analyze the company's quarterly results and gain additional insights into the company's financial performance.

Ajanta Pharma Ltd Stock Price

A company's stock price can be influenced by numerous factors such as news, changes in market trends, or investor sentiment. Through Ticker, investors have access to accurate and real-time stock prices that can help them make informed decisions about buying or selling stocks.

Ajanta Pharma Ltd Price Chart

Price charts are an essential tool for traders and investors alike to track a company's stock performance over time. Ajanta Pharma’s stock price chart allows investors to analyze the movement of the stock price, helping them make tactical investment decisions.

Ajanta Pharma Ltd News and Concall

Keeping abreast of company news is crucial for investors to stay informed of any critical developments that could impact the company's performance. Ajanta Pharma's news and concall updates can be accessed through Ticker's pre-built screening tool.

Ajanta Pharma Ltd Transcripts and Investor Presentations

Transcripts and investor presentations provided by the company offer valuable insights into the company's operations, growth strategy, and performance. Ticker offers downloadable transcripts and investor presentations, allowing investors to track the company's progress.

Ajanta Pharma Ltd Promoters

Ajanta Pharma has a strong group of promoters focused on driving the company forward and creating value for shareholders. Ticker provides detailed information about the promoters of Ajanta Pharma, to help investors gain a better understanding of the company.

Ajanta Pharma Ltd Shareholders

Understanding the company's shareholders is key to understanding how the company is being managed. Investors can gain detailed insights into Ajanta Pharma's shareholders through ticker pre-built screening tool.

Ajanta Pharma Ltd ROCE

The Return on Capital Employed (ROCE) is a key financial ratio used to assess a company's profitability and efficiency in utilizing its capital investments. Our stock analysis page provides the ROCE data for Ajanta Pharma Ltd, enabling investors to evaluate the company's ability to generate returns on its capital employed. This ratio indicates the percentage of profit a company earns in relation to the total capital it has invested. Detailed information on Ajanta Pharma Ltd's ROCE can be found in the financials table or ratio section of our website.

Ajanta Pharma Ltd EBITDA

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure used to assess a company's operational performance and profitability. Our stock analysis page offers the EBITDA data for Ajanta Pharma Ltd, allowing investors to analyze the company's earnings generated solely from its core business operations. By excluding non-operating expenses, EBITDA provides a clearer picture of a company's financial health. Access the detailed EBITDA figures for Ajanta Pharma Ltd in the financials table or ratio section on our website.

Ajanta Pharma Ltd DPS

DPS stands for Dividends Per Share, and it represents the portion of a company's profits distributed to its shareholders in the form of dividends. Our stock analysis page showcases the DPS data for Ajanta Pharma Ltd, allowing investors to monitor the dividend history and track the company's dividend payout ratio. Dividends are a crucial aspect of investment returns, and through our website, you can easily access the DPS information for Ajanta Pharma Ltd in the financials table or ratio section.

Ajanta Pharma Ltd EPS

EPS, or Earnings Per Share, is a widely used financial metric that measures the profitability of a company on a per-share basis. Our stock analysis page provides the EPS data for Ajanta Pharma Ltd, allowing investors to evaluate the company's profitability and track its earnings growth over time. EPS is an essential factor in determining a stock's valuation and potential returns. Detailed information on Ajanta Pharma Ltd's EPS can be found in the financials table or ratio section on our website. 

Ajanta Pharma's Equity and Liabilities: A Steady Growth

Over the years, Ajanta Pharma has shown a promising increase in its equity and liabilities, from Rs 3,327.87 Cr in March 2020 to Rs 4,217.44 Cr by March 2024. A notable jump in share capital in March 2023 signifies a strategic move to bolster the company’s financial structure.

Ajanta Pharma's Reserves: Solidifying Financial Health

The total reserves of Ajanta Pharma have consistently grown from Rs 2,443.76 Cr in March 2020 to Rs 3,388.30 Cr in March 2024. This upward trajectory indicates a strong reinvestment capability and a resilient financial foundation.

Ajanta Pharma Maintains a Debt-Free Stance

Ajanta Pharma stands out with a remarkable debt-free record throughout the observed period, underscoring its prudent financial management and low-risk profile which is an exceptional aspect in its financial narrative.

Ajanta Pharma's Assets: Diversified and Expanding

The company’s asset base expanded from Rs 3,327.87 Cr to Rs 4,217.44 Cr between March 2020 and March 2024. The growth in current assets and a moderate increase in capital WIP (Work in Process) reflect Ajanta Pharma’s strategic investments in its operational capabilities and future growth avenues.

Ajanta Pharma's Liabilities Management: A Balanced Approach

Ajanta Pharma’s approach to managing its liabilities, particularly its current liabilities which saw fluctuations, exhibits a balanced strategy in meeting short-term obligations while sustaining operational efficiency.

This analysis is based on the Standalone Balance Sheet of Ajanta Pharma.

In the broader context, insights into Pharma sector trends can provide valuable context for investors interested in pharmaceutical companies like Ajanta Pharma, enhancing their stock screening processes.

Read More
X